128 related articles for article (PubMed ID: 8627878)
1. Relationship of p53 and bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder.
Glick SH; Howell LP; White RW
J Urol; 1996 May; 155(5):1754-7. PubMed ID: 8627878
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of p53 nuclear overexpression in patients of muscle invasive urinary bladder carcinoma treated with cystectomy.
Hemal AK; Khaitan A; Dinda AK; Gupta NP; Seth A; Dogra PN; Nabi G
Urol Int; 2003; 70(1):42-6. PubMed ID: 12566814
[TBL] [Abstract][Full Text] [Related]
3. Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer.
Pollack A; Wu CS; Czerniak B; Zagars GK; Benedict WF; McDonnell TJ
Clin Cancer Res; 1997 Oct; 3(10):1823-9. PubMed ID: 9815569
[TBL] [Abstract][Full Text] [Related]
4. Reciprocal expression of bcl-2 and p53 oncoproteins in urothelial dysplasia and carcinoma of the urinary bladder.
Li B; Kanamaru H; Noriki S; Yamaguchi T; Fukuda M; Okada K
Urol Res; 1998; 26(4):235-41. PubMed ID: 9759996
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53.
Ong F; Moonen LM; Gallee MP; ten Bosch C; Zerp SF; Hart AA; Bartelink H; Verheij M
Radiother Oncol; 2001 Nov; 61(2):169-75. PubMed ID: 11690683
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of p53, MDM2 and bcl-2 expression in transitional cell carcinoma of the bladder.
Uchida T; Minei S; Gao JP; Wang C; Satoh T; Baba S
Oncol Rep; 2002; 9(2):253-9. PubMed ID: 11836589
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy.
Wu CS; Pollack A; Czerniak B; Chyle V; Zagars GK; Dinney CP; Hu SX; Benedict WF
Urology; 1996 Mar; 47(3):305-10. PubMed ID: 8633392
[TBL] [Abstract][Full Text] [Related]
8. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
10. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates.
Nakopoulou L; Vourlakou C; Zervas A; Tzonou A; Gakiopoulou H; Dimopoulos MA
Hum Pathol; 1998 Feb; 29(2):146-54. PubMed ID: 9490274
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of p53, p21/WAF1, Bcl-2, Bax, Bak and Ki-67 immunoreactivity in pT1 G3 urothelial bladder carcinomas.
Wolf HK; Stöber C; Hohenfellner R; Leissner J
Tumour Biol; 2001; 22(5):328-36. PubMed ID: 11553864
[TBL] [Abstract][Full Text] [Related]
12. The relation between p53 overexpression and lymph node metastases in clinical stage t2 and t3a transitional cell bladder carcinoma.
Uygur MC; Yaman I; Kutluay L; Altuğ U; Erol D
J Exp Clin Cancer Res; 1999 Sep; 18(3):391-5. PubMed ID: 10606186
[TBL] [Abstract][Full Text] [Related]
13. p53 and bcl-2 overexpression as associated risk factors in patients 40 years old or less with transitional cell carcinoma of the bladder.
Asci R; Yildiz L; Sarikaya S; Buyukalpelli R; Yilmaz AF; Kandemir B
Urol Int; 2001; 67(1):34-40. PubMed ID: 11464113
[TBL] [Abstract][Full Text] [Related]
14. Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2.
Vollmer RT; Humphrey PA; Swanson PE; Wick MR; Hudson ML
Cancer; 1998 Feb; 82(4):715-23. PubMed ID: 9477105
[TBL] [Abstract][Full Text] [Related]
15. p53 mutation and bcl-2 expression in transitional cell carcinoma of the urinary bladder.
Wu TT; Lee YH; Huang JK
Zhonghua Yi Xue Za Zhi (Taipei); 2001 Jan; 64(1):9-14. PubMed ID: 11310375
[TBL] [Abstract][Full Text] [Related]
16. Relationship of tumor angiogenesis and nuclear p53 accumulation in invasive bladder cancer.
Bochner BH; Esrig D; Groshen S; Dickinson M; Weidner N; Nichols PW; Skinner DG; Cote RJ
Clin Cancer Res; 1997 Sep; 3(9):1615-22. PubMed ID: 9815851
[TBL] [Abstract][Full Text] [Related]
17. Expression of bcl-2 and bcl-X in bladder cancer.
Kirsh EJ; Baunoch DA; Stadler WM
J Urol; 1998 Apr; 159(4):1348-53. PubMed ID: 9507882
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
[TBL] [Abstract][Full Text] [Related]
19. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
Shariat SF; Tokunaga H; Zhou J; Kim J; Ayala GE; Benedict WF; Lerner SP
J Clin Oncol; 2004 Mar; 22(6):1014-24. PubMed ID: 14981102
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of p53 and pRb immunostaining in locally advanced bladder cancer treated with cystectomy.
Jahnson S; Karlsson MG
J Urol; 1998 Oct; 160(4):1291-6. PubMed ID: 9751338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
